Clarivate is an information-services and analytics company that sells structured scientific, intellectual-property and brand data by subscription. Its flagship franchises are the Web of Science citation database (used by universities, funders and researchers), the Derwent patent-intelligence suite and CompuMark/MarkMonitor trademark and brand-protection tools. The business is a classic 'toll road' on research and IP workflows: ~86% of revenue is recurring and ~68% is subscription, sold on multi-year contracts to sticky institutional and corporate customers, at a ~67% gross margin and ~42% adjusted-EBITDA margin. Clarivate was assembled through a debt-funded roll-up (including the 2021 ProQuest acquisition), which is why it carries ~$4.1bn of net debt against a flat-to-shrinking top line. For a reader: think of it as a cash-generative, high-margin data-subscription franchise with a durable installed base, but one that is over-levered, barely growing, and now facing an open-access and general-AI-search threat to the value of its gated databases.
Lifecycle: Turnaround / Restructuring (Stage 6). Clarivate is a mature, ex-LBO information-services roll-up whose organic revenue has been flat-to-negative for three-plus years and which posts GAAP net losses under a heavy amortization load. It is actively restructuring: a “Value Creation Plan” (simplify the model, lift margins and FCF, push AI products) plus the July-2026 agreement to sell its Life Sciences & Healthcare segment to Altaris for $600m to accelerate debt paydown. So we score it on turnaround metrics — recurring-revenue durability, margin and FCF, and balance-sheet survivability — not on growth multiples.
| Sub-signal | Value | Benchmark / context | Score |
|---|---|---|---|
| Revenue trajectory (organic) | 2024 −1.4% · 2025 −0.1% · Q1’26 +0.6%; 2026 guide +0.75–+2.25% recurring | Info-services peers (RELX, TRI) grow mid-single-digits — CLVT is a laggard | 28 |
| Recurring / subscription mix | Recurring 86.5% · Subscription 67.9% (+1.7% organic) · Transactional 13.6% (−2.0%) | High recurring base = sticky revenue; transactional in secular decline | 72 |
| Profitability | Gross margin ~67% · Adj-EBITDA margin ~42% (guide 42.0–43.5%) · GAAP: net loss | Adjusted margins are genuinely strong for the sector; GAAP distorted by amortization | 66 |
| Cash generation | FCF $365m (2025) · 2026 guide $365–$435m · FCF/EV ~7% | Real, recurring FCF — the strongest part of the story; funds the deleveraging | 65 |
| Balance-sheet health | Net debt ~$4.08bn · Net Debt/Adj-EBITDA ~4.2x · EBIT coverage 0.47x / adj-cash coverage ~3.7x · current ratio 0.84 · tangible book −$7.24/sh | Elevated leverage on a flat top line; negative tangible book (all goodwill/intangibles) | 26 |
Moat average ≈ 54 — a moderate, eroding moat: sticky today, structurally challenged over 3–5 years.
| Competitor / threat | Type | Share trajectory | Moat-erosion vector |
|---|---|---|---|
| RELX (Elsevier / LexisNexis) | Direct incumbent | CLVT losing relative ground | Larger, better-capitalised, mid-single-digit grower; out-invests CLVT in analytics/AI. |
| Thomson Reuters | Direct incumbent (IP/legal) | CLVT losing relative ground | Stronger balance sheet and growth in overlapping IP/legal-data workflows. |
| Open-access publishing | Structural substitution | Losing | Free/open citation and article access erodes the value of gated databases (Web of Science). |
| General-purpose AI search (ChatGPT / Claude / Perplexity) | Disruptive entrant | Losing (early) | AI discovery substitutes for paid research/discovery tools; disintermediation risk to the transactional and discovery layers. |
THE ANCHOR — Warranted-Multiple. Discount rate r = 4.54% (UST10Y, macro 2026-07-09) + 4.5% ERP + 1.0% risk add-on (Business Quality 40–64) = 10.04%. Disciplined growth: g_near = ~2% (organic growth is ~0%; even the sector-defensive 6% cap is not earned here, so we use the company's own low-single-digit trajectory), g_term = 2%. Two-stage warranted P/E ≈ 12.7×. Actual clean multiple: at $2.23 on 2026 adjusted EPS guide ~$0.75 → ~3.0×. Actual ÷ warranted ≈ 0.23 → deep in the Attractive band on the anchor.
| Lens | CLVT | Reference | Read |
|---|---|---|---|
| Warranted-multiple anchor (40% wt) | ratio 0.23 | ≤ 0.80 = Attractive | Attractive |
| EV / adj-EBITDA | 5.7× | Info-services peers ~12–16× | Cheap |
| FCF yield (FCF/EV) | ~7% | >5% attractive | Attractive |
| P/S · P/B | 0.58 · 0.30 | Bottom-decile of own 5-yr range | Cheap |
| PEG (growth-adjusted) | n/m (~0% growth) | Low multiple, but no growth to justify a re-rate | Unfavourable |
| Analyst consensus target | $2.50 vs $2.23 (~+12%) | Within 10–20% — modest upside; targets cut ~70% ($8→$3.33→$2.50) | Fair, falling |
| Grades consensus | HOLD (0 SB / 5 B / 11 H / 4 S) | Negative skew | Cautious |
| FMP rating | B- (overall 2/5) | P/B 5/5 & DCF 5/5 vs ROE/ROA/D-E/P-E all 1/5 | Cheap asset, weak returns |
Implied-growth read: at $2.23 on ~7% FCF/EV and 5.7× EV/EBITDA, the market is implying continued decline or stagnation — it is pricing almost no re-acceleration. Our disciplined estimate is ~0–2% organic. So the price does not embed heroic growth; it embeds pessimism. The upside case is mean-reversion of sentiment as leverage falls, not a growth surprise — which is why Quality and Timing, not Valuation, govern the signal.
Primary driver: the health of institutional and corporate spend on research, IP and brand information — and, cutting against it, the structural shift to open-access publishing and general-purpose AI search that disintermediates gated databases. This is a B2B-information/enterprise-software driver, not a commodity, so there is no price-trend overlay; the relevant tape is the organic-growth trajectory and the competitive/technology shift.
| Horizon | Read | Assessment |
|---|---|---|
| Historical (25%) | Organic growth flat-to-negative 3+ yrs (2024 −1.4%, 2025 −0.1%); transactional revenue in secular decline; targets cut ~70%. | Deteriorating |
| Current (50%) | Q1’26 organic +0.6%, ACV +1.6% — stabilising but barely positive. Budget pressure at universities/pharma; open-access + AI substitution live. | Weak / headwind |
| Forward (25%) | 2026 guide +0.75–+2.25% recurring organic. AI products (IPOne, Nexus Connect, WoS Research Assistant) are the swing factor — unproven. Consensus sceptical. | Uncertain, tilted down |
Driver score 40 — Headwind (mild). The driver is not eligible to amplify (needs ≥ 65 tailwind or ≤ 35 for STRONG). It is a mild headwind: it does not push the base signal to STRONG SELL (score is 40, not ≤ 35, and the base is HOLD which never amplifies), but it removes any tailwind support and keeps the near-term risk to the downside. The thesis-invalidation floor: organic growth turning decisively negative again (worse than −2%), or a visible acceleration of database churn to AI/open-access, would break the turnaround case and take the name from HOLD toward SELL.
Regime is Higher-for-Longer / Stagflation-lite. Mapping CLVT via its GICS classification (Professional/Information Services — closest ETF proxies XLK and XLI): XLK reads short N / med O / long O; XLI reads short O / med O / long SO. Anchored on the medium horizon that is a mild macro tailwind, but for CLVT the company-specific structural story (leverage + flat organic growth + AI/open-access threat) overwhelms any sector-macro read — so the honest economic pressure is Neutral. Because the base signal is HOLD across all horizons (and HOLD never amplifies), Economic Alignment leaves the signal unchanged regardless. Stance Neutral, conviction 45, informational only.
Source: sector-map (GICS Professional/Information Services → XLK/XLI proxy) · Macro report 2026-07-09
Risk-reward: unfavourable for a long entry. Price $2.23 sits just above the 52-week low of $1.66 and below every major moving average (daily SMA50 $2.42, SMA200 $2.87; weekly and monthly stacks all bearish). Multi-timeframe confluence is strongly bearish — monthly, weekly and daily all downtrends/support-breakdown; only the intraday frames are trying to stabilise. Daily RSI ~48 is neutral (no oversold-bounce signal), so there is no mean-reversion trigger firing. The nearest support is $1.90–$1.91, then $1.66; a stop below $1.90 is close but the trend gives no edge to buying here.
| Sub-signal | Read | Score |
|---|---|---|
| MTF trend confluence | Strongly bearish (monthly/weekly/daily downtrends) | 15 |
| Relative strength | 52-wk return ~−44%; underperforming SPY and sector badly on 1m/3m | 15 |
| Position in 52-wk range | ~10% off the low — beaten down (value or falling knife) | 20 |
| Sentiment (analyst grades) | Barclays Underweight (maintained 7 Jul); Goldman Buy→Neutral (Jan), MS→Underweight (Dec), Jefferies Buy→Hold; consensus HOLD | 25 |
| Catalyst layer | Q2 earnings ~end-July; Altaris close pending (H2’26) — both binary-ish. Moderate clustering. | 45 |
Sentiment is bearish and the tape is broken. There is no confirmed timing path for a long — which caps the Short signal and keeps the entry ladder at Wait (see §12).
| Date | Event | Impact | Forecast | Previous | Relevant? | Why |
|---|---|---|---|---|---|---|
| 2026-07-14 | CPI / Core CPI (Jun) YoY | High | 3.9% / 2.9% | 4.2% / 2.9% | ⚠ Indirect | Rate path → growth-multiple sentiment; low direct CLVT sensitivity |
| 2026-07-30 | Q2 2026 earnings (est.) | High | Adj-EPS ~$0.18–0.20 | Q1 beat | ✅ Yes | The key CLVT-specific catalyst — organic-growth & deleveraging read; sets the next update |
| H2 2026 | Altaris LS&H sale close | Medium | $525m cash | — | ✅ Yes | Deleveraging + margin-mix uplift; needs regulatory approval |
| Date | Event | Actual | Forecast | Surprise | Impact |
|---|---|---|---|---|---|
| 2026-07-09 | Existing Home Sales (Jun) | 4.09M | 4.2M | −2.6% below | Neutral for CLVT |
| 2026-07-08 | FOMC Minutes | — | — | On-hold tone | Neutral — rates not rising (relevant to Trigger 1) |
| 2026-07-07 | Barclays reiterates Underweight | — | — | Negative | Confirms bearish Street stance |
Low direct macro sensitivity — CLVT is a niche subscription-data name, not rate- or commodity-driven. The load-bearing catalyst is the Q2 print (~end-July): organic-growth and deleveraging progress. The Altaris close in H2 is the deleveraging event. Note for the gates: the FOMC-minutes on-hold tone confirms rates are NOT rising, which is why Do-Not-Buy Trigger 1 (leverage + rising rates) does not fire.
| Timeframe | Trend | Direction | RSI | MACD | Key S/R | Breakout | Vol |
|---|---|---|---|---|---|---|---|
| Monthly | Downtrend | Bearish ↓ | 35 | −, hist turning | S 1.66 / R 7.15 | Support breakdown | 0.7× |
| Weekly | Downtrend | Bearish ↓ | 44 | −, flat | S 1.66–2.10 / R 3.20 | Support breakdown | 1.9× |
| Daily | Strong downtrend | Bearish ↓ | 48 | −, hist up | S 1.90 / R 2.87 | Support breakdown | 0.8× |
| Hourly | Weakening | Neutral → | 49 | −, turning | S 2.06 / R 2.58 | Resist. breakout | 0.1× |
| 15-min | Recovering | Neutral → | 47 | flat | S 2.12 / R 2.32 | Resist. breakout | 0.0× |
| Confluence: Strongly Bearish · MTF Score 22 | |||||||
Every higher timeframe (monthly, weekly, daily) is in a confirmed downtrend with a support breakdown; the stock is below its SMA50 ($2.42) and SMA200 ($2.87) on the daily. Only the intraday frames are trying to stabilise off the $2.10–2.20 area — a counter-trend bounce inside a larger downtrend, not a reversal. The textbook read is 'sell the rip in a downtrend': rallies into $2.42 (SMA50) / $2.62–2.87 are more likely to stall than to break. A long entry has no timing edge here; the reachable confirmation would be a daily reclaim of the SMA50 on volume, or a tested higher-low bounce off $1.90 support.
CLVT 6-month daily (Jan–Jul 2026). A steep breakdown from ~$3.40 to a $1.66–2.90 range; a Feb capitulation flush, an Apr–May relief bounce to ~$2.87 that failed, and a slide back toward the lows. Below SMA50 and SMA200 — a broken tape.
The turnaround lands: organic growth re-accelerates toward the top of guide (~+2%), the Altaris sale closes and FCF-funded paydown drops leverage toward 3.0x, and the AI products (IPOne, Nexus Connect) show early traction that reframes the AI threat as an opportunity. Sentiment mean-reverts off distressed levels and the multiple re-rates from ~5.7x to ~7–8x EV/EBITDA. ~+57% from $2.23.
Muddle-through: organic growth stays roughly flat (0 to +1%), the divestiture closes and leverage grinds down slowly on FCF, but there is no growth re-acceleration and the structural threat keeps a lid on the multiple. The stock roughly holds its distressed valuation, trading the $1.90–$2.70 range around fair value. Cheap on cash, but no catalyst to close the gap. Roughly flat from $2.23.
The value trap springs: organic growth turns decisively negative again (worse than −2%) as open-access and AI-search accelerate database churn (competitive trigger — RELX/TRI out-execute, AI substitution bites), FCF guidance is cut, and the leverage cushion thins as floating-rate (SOFR) interest stays high under Higher-for-Longer. A further impairment and a guide-down take the multiple lower on a shrinking EBITDA base. ~−37% to the low-$1.40s, testing/undercutting the $1.66 low.
Forecast: Entry ladder reads WAIT (0 of 3 paths met). The most reachable path is Technical — a daily reclaim of the SMA50 ($2.42) on volume, or a tested higher-low off $1.90 support. FORECAST: no path likely inside 2–3 weeks at the current trajectory (price below a falling SMA50 in a confirmed downtrend); a positive Q2 print (~end-July) or a confirmed Altaris close with an explicit leverage step-down is the more likely trigger — catalyst-dependent, CONFIDENCE Low-Moderate. The Fundamental path only opens if the driver stops being a headwind (organic growth re-accelerating), which the numbers do not yet support.
Forecast: For a holder: Thesis-Invalidation is LIVE (2-of-N: revenue below sector median + driver headwind, plus Gate 1) → action Reduce — trim into strength, don't add. The hard Stop-Loss ($1.90 then $1.66) is ~15–25% below and, given the downtrend, is a realistic risk on a bad Q2 print (RISK TRIGGER: Q2 earnings ~end-July). This is not a fresh-buy set-up.
What you're risking: buying into a confirmed multi-timeframe downtrend near the 52-week low, ahead of a binary Q2 print, with Gate 1 (distress) live and organic growth flat. The hard stop ($1.90) is ~15% down; the bear case is ~−37%. No entry rule is met — the ladder says Wait.
What you're gaining: a statistically cheap, cash-generative subscription asset (EV/EBITDA 5.7×, FCF/EV ~7%), plus two free-ish call options — deleveraging (4.2x→3.0x) and AI re-monetisation — the market prices at ~zero. Net read: the risk-reward is roughly symmetric and catalyst-dependent; waiting for the Q2 print or a technical reclaim of $2.42 materially improves the deal. Acting now buys a value trap on hope, not on an edge.
What you're giving up: the deleveraging + AI optionality and any mean-reversion of distressed sentiment; you'd be selling roughly at fair value ($2.38), not below it.
What you're protecting: capital against a live value-trap bear ($1.40) and a broken tape. For a holder, Thesis-Invalidation is live (Reduce) but no hard stop is triggered yet. Net read: this is a hold/trim zone, not a forced exit — reduce into strength, keep a stop under $1.90, and let the Q2 print and Altaris close decide the next move.
Position sizing not computed — specify your portfolio allocation and role for sizing guidance.
{
"ticker": "CLVT",
"company": "Clarivate Plc",
"currency": "USD",
"date": "2026-07-12",
"version": "v6",
"exchange": "NYSE",
"exchange_ticker": "NYSE:CLVT",
"isin": "JE00BJJN4441",
"api_ticker": "CLVT",
"analysis_status": "donatien-pick",
"user_horizon": null,
"user_allocation_pct": null,
"portfolio_role": null,
"lifecycle_stage": "turnaround",
"price_at_rating": 2.23,
"signal_short": "HOLD",
"signal_medium": "HOLD",
"signal_long": "HOLD",
"primary_signal": "HOLD",
"quality_score": 42,
"quality_detail": {
"industry_benchmark_name": "Recurring-revenue durability + FCF conversion (turnaround lens)",
"industry_benchmark_value": 48,
"industry_benchmark_score": 48,
"moat_score": 54,
"recurring_revenue_pct": 86.5,
"adj_ebitda_margin_pct": 42,
"organic_growth_pct": 0.0,
"roic_note": "GAAP ROE/ROA negative; FMP 1/5",
"capital_allocation": 55,
"management_skin_in_game": 45
},
"valuation_score": 70,
"valuation_detail": {
"warranted_multiple": 12.7,
"actual_multiple": 3.0,
"val_multiple_basis": "company-adjusted P/E ($0.75 adj EPS); GAAP is a net loss",
"discount_rate_r": 0.1004,
"risk_free_10y": 0.0454,
"g_near": 0.02,
"g_term": 0.02,
"warranted_ratio": 0.23,
"val_band": "attractive",
"ev_ebitda": 5.7,
"fcf_yield_on_ev_pct": 7.2,
"price_to_sales": 0.58,
"price_to_book": 0.3,
"net_debt_to_ebitda": 4.2,
"net_debt_usd_bn": 4.08,
"interest_coverage_ebit": 0.47,
"interest_coverage_adj_ebitda": 3.7,
"implied_growth_rate": 0.0,
"consensus_growth_rate": 1.0,
"historical_valuation_decile": 1
},
"nonop_pct_of_net_income": "n/m (GAAP net loss; earnings DEPRESSED by ~$736m/yr amortization, not inflated)",
"clean_pe": 3.0,
"clean_peg": null,
"timing_score": 22,
"timing_detail": {
"mtf_confluence": 22,
"risk_reward_score": 20,
"relative_strength_vs_spy": -44,
"relative_strength_vs_sector": -30,
"catalyst_clustering_score": 45,
"dynamic_macro_weight": 0.1
},
"driver_score": 40,
"driver_label": "Headwind (mild)",
"driver_name": "Enterprise research/IP-information spend + AI/open-access disruption",
"driver_commodity_trend": "n/a (non-commodity name)",
"economic_alignment_stance": "Neutral",
"economic_alignment_conviction": 45,
"economic_alignment_pressure": "Neutral",
"economic_alignment_source": "sector-map",
"macro_report_date": "2026-07-09",
"competitive_share_trajectory": "losing",
"competitive_threat_level": "elevated",
"overall_confidence": 48,
"fair_value_est": 2.38,
"stop_loss": 1.9,
"target_price": 2.5,
"scenario_bull_target": 3.5,
"scenario_base_target": 2.3,
"scenario_bear_target": 1.4,
"analyst_consensus_target": 2.5,
"analyst_target_high": 2.5,
"analyst_target_low": 2.5,
"analyst_target_upside_pct": 12.1,
"analyst_grades_consensus": "Hold",
"analyst_bullish_pct": 25,
"analyst_coverage_count": 20,
"fmp_rating": "B-",
"fmp_overall_score": 2,
"recent_upgrades_30d": 0,
"recent_downgrades_30d": 0,
"entry_groups_met": 0,
"entry_conviction": "Wait",
"exit_groups_live": 1,
"exit_action": "Reduce",
"hard_gate_state": "caution",
"gates_triggered": [
"Gate 1 \u2014 Financial Distress (interest-coverage arm: EBIT coverage 0.47\u00d7 < 1.5\u00d7)"
],
"do_not_buy_triggers": [],
"dnb_checked_not_fired": [
"Trigger 1 (leverage + rising rates): NOT fired \u2014 rates on-hold not rising; near-term maturity walls cleared (TLB to 2031); $600m divestiture earmarked for paydown",
"Trigger 3 (persistent negative revisions): NOT fired \u2014 price has repriced ~\u221253% off highs, near 52wk low; second prong (price hasn't repriced) fails",
"Trigger 5 (structural threat): NOT fired as override \u2014 real elevated AI/open-access threat but already priced as distressed; carried in Bear + Competitive"
],
"next_update_date": "2026-07-30",
"next_update_basis": "Q2 2026 earnings ~end-Jul +1d (est.); capped at +14d default",
"finder_ticker": null,
"finder_exchange": null
}